<DOC>
	<DOCNO>NCT00022412</DOCNO>
	<brief_summary>RATIONALE : Doxercalciferol may effective way treat localized prostate cancer surgery . PURPOSE : Randomized phase II trial study effectiveness give doxercalciferol surgery treat patient localized prostate cancer .</brief_summary>
	<brief_title>Doxercalciferol Before Surgery Treating Localized Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether doxercalciferol modulates intermediate endpoint biomarkers development prostate cancer patient localized prostate cancer . - Assess toxicity drug patient . OUTLINE : This randomize , open-label , multicenter study . Patients randomize one 2 arm . - Arm I : Patients receive doxercalciferol daily 28 day . Patients undergo prostatectomy . - Arm II : Patients undergo observation 28 day . Patients undergo prostatectomy . PROJECTED ACCRUAL : A total 60 patient ( 30 per arm ) accrue study within 18 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm localized adenocarcinoma prostate Candidate prostatectomy PATIENT CHARACTERISTICS : Age : 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.4 mg/dL AST great 3 time normal Renal : Creatinine great 2.0 mg/dL Calcium great 10.2 mg/dL No idiopathic urinary calcium stone disease PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : No prior hormonal therapy prostate cancer No concurrent hormonal therapy , include luteinizing hormonereleasing hormone agonist , antiandrogens , glucocorticoid , ketoconazole , finasteride , diethylstilbestrol , progestins Radiotherapy : No prior brachytherapy external beam radiotherapy prostate cancer Surgery : See Disease Characteristics Other : At least 7 day since prior vitamin D therapy calcium supplement No concurrent vitamin D analogues calcium supplement No concurrent magnesiumcontaining antacid No concurrent thiazidecontaining diuretic No concurrent phenytoin , phenobarbital , glutethimide , digoxin , digitalis</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
</DOC>